Logo of sarcomaSarcoma
Sarcoma. 2003 Sep-Dec; 7(3-4): 137–148.
PMCID: PMC2395528
PMID: 18521378

Intensity Modulated Radiation Therapy for Retroperitoneal Sarcoma: A Case for Dose Escalation and Organ at Risk Toxicity Reduction

Mary Koshy, Jerome C. Landry,corresponding author Joshua D. Lawson, Charles A. Staley, Natia Esiashvili, Rebecca Howell, Shahram Ghavidel, and Lawrence W. Davis
Author information Copyright and License information Disclaimer

Abstract

Purpose: Radiation therapy for retroperitoneal sarcoma remains challenging because of proximity to surrounding organs at risk (OAR). We report the use of intensity modulated radiation therapy (IMRT) in the treatment of retroperitoneal sarcomas to minimize dose to OAR while concurrently optimizing tumor dose coverage.

Patients and methods: From January 2000 to October 2002, 10 patients (average age 56 years) with retroperitoneal sarcoma and one with inguinal sarcoma were treated with radiation at Emory University. Prescription dose to the planning treatment volume (PTV) was commonly 50.4 at 1.8 Gy/fraction. CT simulation was used in each patient, three patients were treated with 3D-conformal treatment (3D-CRT), and the remaining eight received multi-leaf collimator-based (MLC) IMRT. IMRT treatment fields ranged from eight to 11 and average volume treated was 3498 cc. Optimal 3D-CRT plans were generated and compared with IMRT with respect to tumor coverage and OAR dose toxicity. Dose volume histograms were compared for both the 3D-CRT and IMRT plans.

Results: Mean dose to small bowel decreased from 36 Gy with 3D-CRT to 27 Gy using IMRT, and tumor coverage (V95) increased from 95.3% with 3D-CRT to 98.6% using IMRT. Maximum and minimum doses delivered to the PTV were significantly increased by 6 and 22%, respectively (P = 0.011, P = 0.055). Volume of small bowel receiving > 30Gy was significantly decreased from 63.5 to 43.1% with IMRT compared with conventional treatment (P = 0.043). Seven patients developed grade 2 nausea, three developed grade 2 diarrhea, one had grade 2 skin toxicity, and one patient developed grade 3 liver toxicity (RTOG toxicity scale). No other delayed toxicities related to radiation were observed. At a median follow-up of 58 weeks, there were no local recurrences and only one patient developed disease progression with distant metastasis in the liver.

Conclusions: IMRT for retroperitoneal sarcoma allowed enhanced tumor coverage and better sparing of dose to critical normal structures such as small bowel, liver, and kidney. Escalation of dose has a positive impact on local control for retroperitoneal sarcoma; IMRT may be an effective method to achieve this goal. We are evaluating preoperative dose escalation to 59.4 Gy.

Full Text

The Full Text of this article is available as a PDF (874K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):880–914. [PubMed] [Google Scholar]
  • Zhang G, Chen KK, Manivel C, Fraley EE. Sarcomas of the retroperitoneum and genitourinary tract. J Urol. 1989 May;141(5):1107–1110. [PubMed] [Google Scholar]
  • Glenn J, Sindelar WF, Kinsella T, Glatstein E, Tepper J, Costa J, Baker A, Sugarbaker P, Brennan MF, Seipp C, et al. Results of multimodality therapy of resectable soft-tissue sarcomas of the retroperitoneum. Surgery. 1985 Mar;97(3):316–325. [PubMed] [Google Scholar]
  • Jaques DP, Coit DG, Hajdu SI, Brennan MF. Management of primary and recurrent soft-tissue sarcoma of the retroperitoneum. Ann Surg. 1990 Jul;212(1):51–59. [PMC free article] [PubMed] [Google Scholar]
  • Catton CN, O'Sullivan B, Kotwall C, Cummings B, Hao Y, Fornasier V. Outcome and prognosis in retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1005–1010. [PubMed] [Google Scholar]
  • Fein DA, Corn BW, Lanciano RM, Herbert SH, Hoffman JP, Coia LR. Management of retroperitoneal sarcomas: does dose escalation impact on locoregional control? Int J Radiat Oncol Biol Phys. 1995 Jan 1;31(1):129–134. [PubMed] [Google Scholar]
  • Tepper JE, Suit HD, Wood WC, Proppe KH, Harmon D, McNulty P. Radiation therapy of retroperitoneal soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 1984 Jun;10(6):825–830. [PubMed] [Google Scholar]
  • Hong Linda, Alektiar Kaled, Chui Chen, LoSasso Tom, Hunt Margie, Spirou Spiridon, Yang Jay, Amols Howard, Ling Clifton, Fuks Zvi, et al. IMRT of large fields: whole-abdomen irradiation. Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):278–289. [PubMed] [Google Scholar]
  • Landry Jerome C, Yang Gary Y, Ting Joseph Y, Staley Charles A, Torres William, Esiashvili Natia, Davis Lawrence W. Treatment of pancreatic cancer tumors with intensity-modulated radiation therapy (IMRT) using the volume at risk approach (VARA): employing dose-volume histogram (DVH) and normal tissue complication probability (NTCP) to evaluate small bowel toxicity. Med Dosim. 2002 Summer;27(2):121–129. [PubMed] [Google Scholar]
  • Chao KS, Majhail N, Huang CJ, Simpson JR, Perez CA, Haughey B, Spector G. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol. 2001 Dec;61(3):275–280. [PubMed] [Google Scholar]
  • Lee Nancy, Xia Ping, Quivey Jeanne M, Sultanem Khalil, Poon Ian, Akazawa Clayton, Akazawa Pam, Weinberg Vivian, Fu Karen K. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):12–22. [PubMed] [Google Scholar]
  • Zelefsky MJ, Fuks Z, Happersett L, Lee HJ, Ling CC, Burman CM, Hunt M, Wolfe T, Venkatraman ES, Jackson A, et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol. 2000 Jun;55(3):241–249. [PubMed] [Google Scholar]
  • Willett CG, Suit HD, Tepper JE, Mankin HJ, Convery K, Rosenberg AL, Wood WC. Intraoperative electron beam radiation therapy for retroperitoneal soft tissue sarcoma. Cancer. 1991 Jul 15;68(2):278–283. [PubMed] [Google Scholar]
  • Bortfeld Thomas, Jokivarsi Kimmo, Goitein Michael, Kung Jong, Jiang Steve B. Effects of intra-fraction motion on IMRT dose delivery: statistical analysis and simulation. Phys Med Biol. 2002 Jul 7;47(13):2203–2220. [PubMed] [Google Scholar]
  • Coia LR, Myerson RJ, Tepper JE. Late effects of radiation therapy on the gastrointestinal tract. Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1213–1236. [PubMed] [Google Scholar]
  • Wu Q, Arnfield M, Tong S, Wu Y, Mohan R. Dynamic splitting of large intensity-modulated fields. Phys Med Biol. 2000 Jul;45(7):1731–1740. [PubMed] [Google Scholar]
  • Brennan MF, Casper ES, Harrison LB, Shiu MH, Gaynor J, Hajdu SI. The role of multimodality therapy in soft-tissue sarcoma. Ann Surg. 1991 Sep;214(3):328–338. [PMC free article] [PubMed] [Google Scholar]
  • Stoeckle E, Coindre JM, Bonvalot S, Kantor G, Terrier P, Bonichon F, Nguyen Bui B. Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer. 2001 Jul 15;92(2):359–368. [PubMed] [Google Scholar]
  • van Doorn RC, Gallee MP, Hart AA, Gortzak E, Rutgers EJ, van Coevorden F, Keus RB, Zoetmulder FA. Resectable retroperitoneal soft tissue sarcomas. The effect of extent of resection and postoperative radiation therapy on local tumor control. Cancer. 1994 Feb 1;73(3):637–642. [PubMed] [Google Scholar]
  • McGrath PC, Neifeld JP, Lawrence W, Jr, DeMay RM, Kay S, Horsley JS, 3rd, Parker GA. Improved survival following complete excision of retroperitoneal sarcomas. Ann Surg. 1984 Aug;200(2):200–204. [PMC free article] [PubMed] [Google Scholar]
  • Storm FK, Mahvi DM. Diagnosis and management of retroperitoneal soft-tissue sarcoma. Ann Surg. 1991 Jul;214(1):2–10. [PMC free article] [PubMed] [Google Scholar]
  • Jaques DP, Coit DG, Hajdu SI, Brennan MF. Management of primary and recurrent soft-tissue sarcoma of the retroperitoneum. Ann Surg. 1990 Jul;212(1):51–59. [PMC free article] [PubMed] [Google Scholar]
  • Cody HS, 3rd, Turnbull AD, Fortner JG, Hajdu SI. The continuing challenge of retroperitoneal sarcomas. Cancer. 1981 May 1;47(9):2147–2152. [PubMed] [Google Scholar]
  • Kilkenny JW, 3rd, Bland KI, Copeland EM., 3rd Retroperitoneal sarcoma: the University of Florida experience. J Am Coll Surg. 1996 Apr;182(4):329–339. [PubMed] [Google Scholar]
  • Bevilacqua RG, Rogatko A, Hajdu SI, Brennan MF. Prognostic factors in primary retroperitoneal soft-tissue sarcomas. Arch Surg. 1991 Mar;126(3):328–334. [PubMed] [Google Scholar]
  • Heslin MJ, Lewis JJ, Nadler E, Newman E, Woodruff JM, Casper ES, Leung D, Brennan MF. Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management. J Clin Oncol. 1997 Aug;15(8):2832–2839. [PubMed] [Google Scholar]
  • Suit HD, Mankin HJ, Wood WC, Gebhardt MC, Harmon DC, Rosenberg A, Tepper JE, Rosenthal D. Treatment of the patient with stage M0 soft tissue sarcoma. J Clin Oncol. 1988 May;6(5):854–862. [PubMed] [Google Scholar]
  • Pollack A, Zagars GK, Goswitz MS, Pollock RA, Feig BW, Pisters PW. Preoperative vs. postoperative radiotherapy in the treatment of soft tissue sarcomas: a matter of presentation. Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):563–572. [PubMed] [Google Scholar]
  • O'Sullivan Brian, Davis Aileen M, Turcotte Robert, Bell Robert, Catton Charles, Chabot Pierre, Wunder Jay, Kandel Rita, Goddard Karen, Sadura Anna, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002 Jun 29;359(9325):2235–2241. [PubMed] [Google Scholar]
  • Sindelar WF, Kinsella TJ, Chen PW, DeLaney TF, Tepper JE, Rosenberg SA, Glatstein E. Intraoperative radiotherapy in retroperitoneal sarcomas. Final results of a prospective, randomized, clinical trial. Arch Surg. 1993 Apr;128(4):402–410. [PubMed] [Google Scholar]
  • Gieschen HL, Spiro IJ, Suit HD, Ott MJ, Rattner DW, Ancukiewicz M, Willett CG. Long-term results of intraoperative electron beam radiotherapy for primary and recurrent retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):127–131. [PubMed] [Google Scholar]
  • Alektiar KM, Hu K, Anderson L, Brennan MF, Harrison LB. High-dose-rate intraoperative radiation therapy (HDR-IORT) for retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):157–163. [PubMed] [Google Scholar]
Articles from Sarcoma are provided here courtesy of Hindawi Limited